healthevidencedigest

Tag: hematology

  • Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

    Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

    The essentials: On June 8, 2026, the FDA approved an expanded indication for Hympavzi (marstacimab-hncq, Pfizer) to include two additional patient populations: patients aged 12 years and older with hemophilia A or B who have inhibitors, and pediatric patients aged 6 to 11 years with hemophilia A or B with or without inhibitors. Hympavzi was originally approved in October 2024 for patients aged 12 years and older without inhibitors. The complete current indication: routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 6 years and older with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency), with or without inhibitors. First-in-class designations from the expanded approval: Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. Mechanism: Hympavzi targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulant that brakes the initiation of coagulation. By inhibiting TFPI, marstacimab restores the coagulation pathway in a way that works regardless of whether the patient is deficient in factor VIII or factor IX, and regardless of whether inhibitory antibodies are present against those factors. This is why it works in both hemophilia A and B, and in patients with inhibitors. The clinical basis: Phase 3 BASIS trial (NCT03938792) inhibitor cohort and Phase 3 BASIS KIDS trial (NCT05611801). BASIS inhibitor cohort: 93% reduction in mean treated annualized bleeding rate (ABR) versus on-demand bypassing agent therapy (1.4 [95% CI 0.9 to 2.3] versus 19.8 [95% CI 16.1 to 24.3]; ratio 0.07 [95% CI 0.04 to 0.12]; p less than 0.0001). BASIS KIDS (ages 6 to 17): mean ABR 1.8 versus historical model-based mean ABR 3.6 with prior routine prophylaxis. Pediatric inhibitor subgroup (ages 6 to under 18; n=14): mean ABR 1.4 (99% CI 0.5 to 4.5) versus historical mean ABR 18.9 (99% CI 14.2 to 25.2). Ages 6 to 11 cohort (n=7): mean ABR 1.3 (99% CI 0.5 to 3.4). Warnings: thromboembolic events occurred in 2 of 259 patients in the open-label extension study; hypersensitivity reactions; embryo-fetal toxicity; increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2. Dosing: once weekly subcutaneous injection; available as 75 mg/0.5 mL and 150 mg/mL prefilled syringe or autoinjector pen. No routine treatment-related laboratory monitoring required.

    Hemophilia is, at its core, a disease of imbalance. The coagulation cascade that allows blood to clot and stop bleeding is a tightly regulated system of amplification, and in hemophilia A or B, a critical amplifier is missing or deficient. The consequences, when left untreated or inadequately treated, are relentless: joint bleeds that destroy cartilage and deform limbs, muscle hemorrhages that compress nerves and blood vessels, and intracranial bleeding that can be fatal. For patients with a specific complication called inhibitors, even the standard replacement therapy stops working, leaving them in a position where a category of medications designed to save their lives has become ineffective against their own immune response.

    Hympavzi (marstacimab-hncq), originally approved in October 2024, takes an entirely different approach to hemophilia prophylaxis. Rather than replacing the deficient clotting factor, it blocks a natural brake on the coagulation system: tissue factor pathway inhibitor (TFPI). On June 8, 2026, the FDA expanded Hympavzi’s approved indication to two of the groups most in need of this approach: patients with hemophilia A or B who have inhibitors (where factor replacement therapy either cannot work or works inadequately), and children aged 6 to 11 years, the youngest pediatric age group that can benefit from a once-weekly subcutaneous prophylactic therapy.

    This post covers what hemophilia is, why inhibitors represent such a significant clinical challenge, how the TFPI mechanism works and why it is effective across both hemophilia types and inhibitor-positive patients, what the BASIS and BASIS KIDS trial data shows, and what the expanded approval means for families and clinicians managing these patients.

    What Hemophilia Is: A Brief Overview

    Hemophilia is a rare, X-linked recessive bleeding disorder caused by deficiency or dysfunction of specific coagulation factors. Two major types are recognized:

    Hemophilia A is caused by deficiency or dysfunction of factor VIII (FVIII). It is the more common type, affecting approximately 1 in 5,000 male births.

    Hemophilia B is caused by deficiency or dysfunction of factor IX (FIX). It affects approximately 1 in 25,000 male births.

    Both conditions result in a dysfunctional coagulation cascade, the sequential activation of clotting proteins that ultimately converts fibrinogen to fibrin and forms a stable blood clot. Without adequate FVIII or FIX activity, the intrinsic pathway of coagulation cannot amplify adequately, resulting in delayed, insufficient clot formation. Minor injuries that healthy individuals handle without consequence become prolonged bleeding events in hemophilia. Spontaneous joint and muscle bleeds, which occur without obvious trauma, are a hallmark of severe hemophilia and are responsible for the progressive arthropathy (joint destruction) that historically defined the long-term morbidity of the disease.

    The standard of care for moderate to severe hemophilia has been prophylactic factor replacement: infusing FVIII or FIX concentrate on a scheduled basis, typically two to three times per week for IV formulations or less frequently for extended half-life products, to maintain factor levels high enough to prevent spontaneous bleeding. This approach has dramatically improved outcomes over the past four decades. It requires, however, venous access and intravenous administration, which is particularly challenging in young children whose veins are small and who may require port placement.

    The inhibitor problem

    Inhibitors are neutralizing antibodies against the infused clotting factor, most commonly FVIII in hemophilia A. They develop in approximately 30% of patients with severe hemophilia A and in a smaller proportion of hemophilia B patients, typically early in treatment. When inhibitors are present, the infused factor is rapidly neutralized before it can participate in clotting, and standard prophylaxis becomes ineffective.

    Managing hemophilia with inhibitors has historically required bypassing agents, products that activate the coagulation cascade at steps downstream of where FVIII and FIX normally act: recombinant factor VIIa (NovoSeven) and activated prothrombin complex concentrate (aPCC, FEIBA). These agents work differently from standard factor replacement and are less precisely dosed, making achieving predictable bleeding protection more challenging. Their use is also expensive, requires intravenous administration, and when used on-demand (only when bleeding occurs) rather than prophylactically, leaves patients with significant residual bleeding burden.

    Why non-factor therapies are a breakthrough for inhibitor patients The development of non-factor hemostatic therapies, which restore hemostasis by mechanisms that bypass the deficient factor entirely, represents one of the most significant advances in hemophilia management in decades. Emicizumab (Hemlibra), approved in 2017 for hemophilia A with inhibitors, was the first such therapy and demonstrated dramatic reductions in bleeding rates in a population that had previously had very limited prophylactic options. It works by bridging FIXa and FX, mimicking the co-factor function of FVIII specifically. However, because emicizumab bridges FIXa (factor IX in activated form), it works only in hemophilia A: it provides no benefit in hemophilia B because FIX is not a bridging partner for its mechanism. Marstacimab’s TFPI inhibition mechanism is active in both hemophilia A and hemophilia B regardless of inhibitor status, because it restores hemostasis upstream of where either FVIII or FIX deficiency disrupts the cascade. This is why Hympavzi’s expanded indication covers both hemophilia types and both inhibitor-positive and inhibitor-negative patients.

    The Science: How Marstacimab Works

    Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant protein. It functions as a feedback inhibitor of the extrinsic pathway of coagulation: after tissue factor and factor VIIa initiate clotting in response to vascular injury, TFPI rapidly inhibits the TF-FVIIa-FXa complex, effectively braking the initial clotting signal after it has had time to initiate.

    In healthy individuals, this brake is appropriate. The extrinsic pathway generates only a small initial burst of thrombin, and the intrinsic pathway (which requires FVIII and FIX) amplifies this initial signal to generate the large amounts of thrombin needed for stable clot formation. When FVIII or FIX is deficient, the initial thrombin burst generated by the extrinsic pathway is inadequate, and the amplification step through the intrinsic pathway cannot compensate. TFPI’s braking of the extrinsic pathway further limits the already insufficient hemostatic response.

    Marstacimab is a human monoclonal antibody that targets the Kunitz 2 (K2) domain of TFPI with high specificity. The K2 domain is the site through which TFPI inhibits FXa, a critical downstream clotting protein. By blocking the K2 domain, marstacimab prevents TFPI from inhibiting FXa as efficiently. This allows the coagulation cascade to generate more thrombin from the extrinsic pathway initiation step, partially compensating for the deficient intrinsic amplification. The result is a shift in the coagulation balance toward clot formation even in the absence of adequate FVIII or FIX.

    Critically, this mechanism functions regardless of:

    • Whether the patient is deficient in FVIII (hemophilia A) or FIX (hemophilia B)
    • Whether inhibitory antibodies are present against FVIII or FIX
    • The severity of the underlying factor deficiency

    Because marstacimab acts on a checkpoint in the coagulation cascade that is common to both hemophilia types and is entirely upstream of where inhibitors act against replacement factors, it provides hemostatic coverage across the full breadth of the expanded indication.

    The Original Approval and What the Expansion Adds

    Original approval (October 2024)

    Hympavzi was initially approved in October 2024 for routine prophylaxis in patients aged 12 years and older with hemophilia A without FVIII inhibitors or hemophilia B without FIX inhibitors, based on the Phase 3 BASIS trial in the non-inhibitor cohort.

    The June 2026 expansion

    The June 8, 2026 expansion adds two critically important populations:

    Population 1: Patients aged 12 years and older with hemophilia A or B who have inhibitors. This is the group with the most limited treatment options prior to this approval, for whom on-demand bypassing agents were often the only recourse for bleeding management.

    Population 2: Pediatric patients aged 6 to 11 years with hemophilia A or B, with or without inhibitors. This extends Hympavzi’s reach to younger children, a population in whom venous access for IV therapy is a significant practical challenge, and for whom a once-weekly subcutaneous injection is potentially far more manageable than frequent IV infusions.

    Together, the expanded and original indications give Hympavzi a single consolidated label: routine prophylaxis for adults and pediatric patients aged 6 years and older with hemophilia A or B, with or without inhibitors.

    The Clinical Evidence: BASIS Inhibitor Cohort and BASIS KIDS

    BASIS trial (NCT03938792): the inhibitor cohort data

    BASIS (NCT03938792) was a Phase 3, global, open-label trial evaluating marstacimab in patients with hemophilia A or B with and without inhibitors. The trial included an inhibitor cohort of patients who had previously received on-demand (OD) bypassing agent therapy for bleeding episodes. This population represents the clinical severity of inhibitor disease: patients who had not been on prophylaxis and were relying on reactive treatment when bleeds occurred.

    The primary efficacy comparison in the inhibitor cohort was marstacimab prophylaxis versus on-demand bypassing agent therapy. The results were striking:

    OutcomeMarstacimab prophylaxisOn-demand bypassing agent (historical)Comparison
    Mean treated annualized bleeding rate (ABR)1.4 (95% CI 0.9 to 2.3)19.8 (95% CI 16.1 to 24.3)93% reduction; ratio 0.07 (95% CI 0.04 to 0.12); p less than 0.0001

    Source: Clinical Advisor. Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. June 2026. Hematology Advisor. June 2026. Pfizer press release, June 8, 2026.

    A 93% reduction in mean treated annualized bleeding rate compared to on-demand bypassing therapy is a clinically substantial finding. Patients going from a mean treated ABR of approximately 19.8 bleeds per year to 1.4 bleeds per year is a transformation in disease burden. The most devastating consequence of hemophilia with inhibitors has always been the inability to prevent spontaneous joint bleeds because on-demand therapy, by definition, does not begin until bleeding has already started. Each prevented bleed under prophylaxis is a joint or muscle or organ that did not bleed.

    This comparison is against on-demand therapy because patients in the inhibitor cohort had not previously been on prophylaxis. An interpretive note: comparing against on-demand is a favorable comparison for the active treatment; a head-to-head comparison against existing prophylactic bypassing agent regimens would be more demanding. Nonetheless, the magnitude of the reduction is substantial and clinically meaningful.

    BASIS KIDS trial (NCT05611801): the pediatric data

    BASIS KIDS (NCT05611801) was a Phase 3, global, open-label trial evaluating the safety and efficacy of marstacimab in children aged 1 to 17 years with hemophilia A or B, with or without inhibitors. Interim results from this trial supported the FDA’s expanded approval for the 6-to-11-year age group.

    PopulationMean ABR with marstacimabComparison (historical model-based)
    Ages 6 to 17, all patients (overall BASIS KIDS)1.83.6 (prior routine prophylaxis)
    Ages 6 to under 18 with inhibitors (n=14)1.4 (99% CI 0.5 to 4.5)18.9 (99% CI 14.2 to 25.2)
    Ages 6 to 11 cohort (n=7)1.3 (99% CI 0.5 to 3.4)—

    Source: Clinical Advisor. CheckRare. BASIS KIDS NCT05611801.

    The pediatric inhibitor subgroup data is particularly notable: children with hemophilia and inhibitors achieved a mean ABR of 1.4 with marstacimab prophylaxis compared to a historical model-based mean of 18.9 with on-demand bypassing therapy. For the youngest cohort (ages 6 to 11), the mean ABR of 1.3 indicates that the same degree of bleeding rate reduction is achievable in younger children.

    The comparison in BASIS KIDS against historical model-based rates (rather than a randomized parallel arm) is appropriate for a pediatric rare disease trial, where randomizing young children to a control arm receiving inferior therapy would be ethically difficult and practically challenging. The historical modeling approach uses well-characterized natural history data from the hemophilia population to provide a reference benchmark.

    What Makes This Approval Particularly Significant

    The hemophilia B inhibitor gap

    The most significant first-in-class designation from this expansion is that Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. This deserves specific explanation.

    Emicizumab (Hemlibra), the landmark non-factor therapy approved for hemophilia A with inhibitors in 2017, works by bridging activated factor IXa and factor X, mimicking the cofactor function of FVIII. This mechanism is specific to hemophilia A: it does not provide any benefit in hemophilia B because factor IXa is not the relevant enzyme that needs a cofactor. Patients with hemophilia B and inhibitors have therefore had no approved subcutaneous prophylactic non-factor therapy option. For them, marstacimab’s TFPI inhibition mechanism, which is indifferent to whether the underlying deficiency is in FVIII or FIX, represents the first approval in this category.

    Once-weekly subcutaneous administration without routine laboratory monitoring

    Hympavzi is administered once weekly by subcutaneous injection. The therapy does not require routine treatment-related laboratory monitoring, which distinguishes it from many hemophilia treatments that require regular factor level measurement or trough level testing to guide dosing. For families managing pediatric hemophilia, reducing the blood draw burden alongside simplifying the injection schedule to once weekly is a meaningful quality-of-life improvement.

    Patients aged 12 years and older may self-inject after proper training. For children aged 6 to 11, caregiver administration is expected.

    Safety: What the Prescribing Information Covers

    The prescribing information for Hympavzi includes several important warnings:

    Thromboembolic events: Two thromboembolic events occurred among 259 patients in the open-label extension study. Because marstacimab shifts the coagulation balance toward clot formation by removing the TFPI brake on the extrinsic pathway, the theoretical risk of thrombosis is inherent to its mechanism of action. Monitor patients for signs and symptoms of thromboembolic events. The absolute rate was low (2 of 259 patients in the extension), but the mechanism-based concern means clinical vigilance is appropriate.

    Laboratory changes: Increases in fibrin D-dimer and prothrombin fragment 1.2 have been observed with marstacimab. These are laboratory markers of coagulation activation and fibrin turnover. They are consistent with the drug’s mechanism (enhanced coagulation pathway activity) but require awareness in clinical monitoring. Do not interpret elevated D-dimer as diagnostic for thrombosis without clinical correlation in patients receiving marstacimab.

    Hypersensitivity reactions: As with all monoclonal antibodies, hypersensitivity reactions including anaphylaxis may occur. Patients should be informed of the symptoms and instructed to seek immediate medical attention if they occur.

    Embryo-fetal toxicity: Based on the mechanism of action (promoting coagulation), there is a potential for fetal harm. Females of reproductive potential should use effective contraception during treatment.

    Common adverse reactions (2% or greater): Injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.

    What This Means for Patients and Families

    For patients with hemophilia A or B who have inhibitors

    This is the population for whom this expansion matters most urgently. Inhibitor-positive patients, particularly those with hemophilia B inhibitors, have had no approved subcutaneous non-factor prophylactic therapy before this date. The BASIS inhibitor cohort’s 93% reduction in treated ABR compared to on-demand bypassing therapy represents a shift from a reactive management strategy to an active preventive one, with the bleed rate reduction that entails.

    If you or a family member has hemophilia with inhibitors and has been managed with on-demand bypassing agents, a conversation with your hematologist about whether Hympavzi is an appropriate prophylactic option is warranted.

    For families of children aged 6 to 11

    For young children with hemophilia, IV access for factor infusions has historically been the most practically difficult aspect of management, often requiring port placement and the risks that entails. A once-weekly subcutaneous injection administered by a caregiver at home, without routine blood draws for monitoring, represents a materially simpler treatment paradigm for this age group. The BASIS KIDS data showing a mean ABR of 1.3 in the 6-to-11 cohort supports the clinical adequacy of this approach.

    For children with hemophilia B specifically, this is the first approved subcutaneous non-factor prophylactic therapy in this age group, filling a gap that emicizumab’s mechanism could not address.

    For clinicians managing hemophilia

    The complete current Hympavzi indication covers hemophilia A and B, with or without inhibitors, in patients aged 6 years and older. This is a single once-weekly subcutaneous platform applicable across the majority of the hemophilia population. For patients who are appropriate candidates, the elimination of routine treatment-related laboratory monitoring removes a significant ongoing management burden.

    The thromboembolic warning and the D-dimer/prothrombin fragment 1.2 elevations associated with marstacimab require clinical awareness, particularly in patients who may develop thrombotic risk factors over time (surgery, immobilization, pregnancy). Risk-benefit discussions individualized to each patient’s circumstances remain the appropriate framework.

    For related HED coverage on other rare hematologic disease approvals in 2026, see our post on KRESLADI, the first gene therapy approved for severe leukocyte adhesion deficiency type I and our post on Decnupaz (pivekimab sunirine) approved for blastic plasmacytoid dendritic cell neoplasm.

    Sources

    Pfizer FDA approval press release: U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. Pfizer. June 8, 2026.

    Drugs.com approval news: U.S. FDA Approves Pfizer’s Hympavzi for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. drugs.com. June 8, 2026.

    BioPharm International clinical coverage: FDA Expands Pfizer’s Hympavzi Approval to Pediatric Hemophilia Patients and Those with Inhibitors. biopharminternational.com. June 2026.

    Hematology Advisor (BASIS inhibitor data): Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. hematologyadvisor.com. June 2026.

    Clinical Advisor detailed summary: Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. clinicaladvisor.com. June 2026.

    Conexiant clinical summary: FDA Expands Marstacimab Indication in Hemophilia A and B. conexiant.com. June 2026.

    CheckRare clinical coverage: FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia. checkrare.com. June 2026.

    BASIS trial registration: NCT03938792. ClinicalTrials.gov.

    BASIS KIDS trial registration: NCT05611801. ClinicalTrials.gov.

    Priority Review grant (sBLA): FDA Grants Priority Review for HYMPAVZI sBLA. Pfizer. 2026.

    Hympavzi original approval (October 2024): Hympavzi FDA Approval History. drugs.com.

    Hympavzi prescribing information: HYMPAVZI (marstacimab-hncq) Prescribing Information. Pfizer. 2026.

    TFPI biology and marstacimab mechanism: Tissue Factor Pathway Inhibitor. PMC6126283.

    Coagulation cascade: Coagulation Studies. StatPearls. NCBI.

    Hemophilia A overview: Hemophilia A. StatPearls. NCBI.

    Hemophilia B overview: Hemophilia B. StatPearls. NCBI.

    Hemophilia inhibitors: Factor VIII Inhibitors in Hemophilia A. PMC7155173.

    CDC hemophilia overview: Hemophilia. CDC.

    Patient resources: National Hemophilia Foundation | World Federation of Hemophilia | Pfizer Hympavzi patient support

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Hemophilia management is complex and requires individualized assessment by a hematologist experienced in bleeding disorders. Decisions about switching to or initiating Hympavzi should be made in consultation with a treating hematologist who can assess the patient’s inhibitor status, bleeding history, current prophylaxis regimen, and individual risk-benefit profile.
  • Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    📌 The essentials On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib, Incyte), a once-daily extended-release formulation of ruxolitinib, for the same four indications as the original Jakafi: intermediate- or high-risk myelofibrosis (MF) in adults, polycythemia vera (PV) in adults with inadequate response to or intolerance of hydroxyurea, steroid-refractory acute graft-versus-host disease (GVHD) in adults and pediatric patients aged 12 and older, and chronic GVHD after failure of 1 or 2 lines of systemic therapy in adults and pediatric patients aged 12 and older. This is a new dosage form approval, not a new indication. The indications are identical to the original Jakafi. The clinical basis: a randomized, open-label, 2-period, 2-way crossover bioequivalence study (NCT06555081) in 169 healthy adults, showing that 55 mg Jakafi XR once daily is bioequivalent to 25 mg Jakafi twice daily based on steady-state pharmacokinetic measures. Results presented as an ASH 2025 poster (Gong et al. Blood. 2025;146(suppl 1):5045). Safety of Jakafi XR is established from the extensive controlled studies of the original Jakafi across all approved indications: no new safety signals. Available for pharmacy orders beginning May 8, 2026. Critical practical note: Jakafi XR is not a new drug. It delivers the same ruxolitinib molecule at equivalent systemic exposure in a single daily tablet instead of two. Patients who switch should not expect a different clinical effect; the therapeutic benefit comes from the same mechanism and the same total daily drug exposure.

    Patients with myelofibrosis, polycythemia vera, and graft-versus-host disease have been managing chronic conditions for years on a twice-daily regimen. Twice daily means twice daily: morning and evening, 12 hours apart, building those doses into the rhythm of every single day. For patients who are also managing multiple comorbidities with multiple medications, that twice-daily requirement is one of many adherence demands that can compound into a real burden over time.

    On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib), a once-daily extended-release formulation of a drug that has been the standard of care for myelofibrosis and polycythemia vera since 2011 and for steroid-refractory GVHD since 2019 and 2021. The clinical evidence behind the original Jakafi is unchanged. The new formulation simply delivers the same drug at equivalent systemic exposure in a single morning tablet.

    This is not a clinical advance in the sense of a new drug with new efficacy data. It is a formulation advance, removing one daily dose from the schedule of patients who are likely to be on this drug for years.

    What Ruxolitinib Is and Why These Three Conditions Require Long-Term Treatment

    Ruxolitinib is a selective inhibitor of Janus kinase 1 (JAK1) and JAK2, two enzymes that are central to the signaling pathways mediating inflammatory cytokine responses and hematopoietic cell proliferation. JAK1 and JAK2 mediate signaling from multiple cytokine receptors, and their overactivation is the pathological driver in myelofibrosis, polycythemia vera, and GVHD through distinct but related mechanisms.

    Understanding why patients take ruxolitinib for extended periods requires understanding each of the conditions it treats.

    Myelofibrosis

    Myelofibrosis is a myeloproliferative neoplasm in which progressive bone marrow scarring (fibrosis) disrupts normal blood cell production. The fibrosis is driven by inflammatory cytokine overproduction mediated in large part through JAK-STAT pathway activation, often involving somatic mutations in JAK2, CALR, or MPL. The result is progressive anemia, enlargement of the spleen (splenomegaly), constitutional symptoms including debilitating fatigue, night sweats, and weight loss, and over time, the risk of transformation to acute leukemia.

    Ruxolitinib was the first approved therapy to substantially reduce splenomegaly and improve constitutional symptoms in intermediate- and high-risk MF. It does not typically reverse or halt fibrosis progression, but it durably reduces the inflammatory burden that drives many of the disease’s most disabling manifestations. Most patients with MF who respond to ruxolitinib continue it indefinitely, as disease symptoms return on discontinuation.

    Polycythemia vera

    Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by overproduction of red blood cells, often accompanied by elevated white blood cells and platelets, driven almost universally by the JAK2 V617F mutation. The primary risk is thrombosis: the abnormally high blood cell counts and viscosity substantially elevate the risk of stroke, deep vein thrombosis, pulmonary embolism, and other thrombotic events. First-line management involves phlebotomy and aspirin for low-risk patients, and hydroxyurea for high-risk patients. Ruxolitinib is indicated for patients who have had an inadequate response to or are intolerant of hydroxyurea, providing JAK2-targeted suppression of the malignant clone. Again, this is chronic therapy: patients who achieve hematocrit control and symptom relief on ruxolitinib continue it as long as it is effective and tolerated.

    Graft-versus-host disease

    GVHD is a complication of allogeneic stem cell transplantation in which donor immune cells attack the recipient’s tissues. Acute GVHD typically involves the skin, liver, and gastrointestinal tract; chronic GVHD can affect virtually any organ system and is associated with significant morbidity and mortality. Ruxolitinib, by inhibiting JAK-mediated inflammatory cytokine signaling in donor T cells, reduces the inflammatory cascade driving tissue damage. GVHD patients may require treatment for months to years, again placing this in the category of chronic therapy where dosing schedule matters.

    Why a once-daily formulation matters for chronic blood disease management Patients with MF, PV, and GVHD are frequently older adults with multiple conditions managing multiple daily medications. They may also be managing disease symptoms including fatigue, pain, and cytopenias that affect daily function. In this context, the psychosocial and practical dimension of medication burden is well-documented: adherence to twice-daily regimens is consistently lower than once-daily regimens across all chronic disease areas, even when patients understand the clinical importance of each dose. Studies in conditions from hypertension to HIV have shown that reducing dosing frequency from twice daily to once daily improves adherence by 10 to 20%, with downstream improvements in outcomes that compound over years of treatment. For a drug that works as long as it is taken and loses its effect when stopped, that adherence difference is clinically meaningful.

    The Approval Basis: What Bioequivalence Means and Why It Is the Right Standard Here

    The FDA approved Jakafi XR based on a bioequivalence study, not on a new Phase 3 efficacy trial. This is the correct regulatory approach for a new dosage form of an existing drug with well-established efficacy and safety. Understanding why requires understanding what bioequivalence means and what it does not.

    What the bioequivalence study showed

    The pivotal study (NCT06555081) was a randomized, open-label, 2-period, 2-way crossover study in 169 healthy adult participants. Each participant received both Jakafi XR 55 mg once daily and Jakafi 25 mg twice daily in random order, with a washout period between. The study measured key pharmacokinetic parameters at steady state: AUC (area under the concentration-time curve, measuring total drug exposure) and Cmax (peak drug concentration).

    The FDA’s standard for bioequivalence requires that the 90% confidence interval for the ratio of the test (XR) to reference (IR) geometric means for AUC and Cmax falls within 80 to 125%. Jakafi XR met these criteria, confirming that the once-daily extended-release formulation delivers the same total daily ruxolitinib exposure as the twice-daily immediate-release formulation.

    Results were presented at the 2025 American Society of Hematology Annual Meeting (ASH 2025) in a poster by Gong et al. (Blood. 2025;146(suppl 1):5045).

    Pharmacokinetic differences between XR and IR: what matters clinically The extended-release mechanism produces a different concentration-time profile than immediate release, even when total daily exposure is equivalent. Jakafi IR produces two peak concentrations per day (one after each dose) with a trough in between. Jakafi XR produces a single, broader, lower peak with more consistent drug levels throughout the 24-hour dosing interval. For JAK inhibition, which requires sustained target coverage rather than intermittent high-concentration peaks, the flatter pharmacokinetic profile of once-daily XR is biologically appropriate. The trough concentrations between IR doses might theoretically allow partial JAK pathway reactivation; the XR formulation maintains steadier JAK inhibition. Whether this translates into any measurable clinical difference in efficacy or tolerability is not yet established from comparative clinical trial data, but the pharmacological rationale supports the XR approach.

    Why no new Phase 3 trial was required

    Ruxolitinib has been studied in multiple large Phase 3 trials across all approved indications, involving thousands of patients with substantial follow-up. The COMFORT-I and COMFORT-II trials established its efficacy in MF; RESPONSE trials established its efficacy in PV; REACH2 and REACH3 established its efficacy in acute and chronic GVHD respectively. Requiring a new Phase 3 trial to approve a formulation change that delivers identical drug exposure would delay access to the more convenient dosing form without generating scientifically useful information. The FDA’s bioequivalence pathway is precisely designed for this scenario.

    The Full Jakafi/Jakafi XR Approved Indication Picture

    Both Jakafi (original, twice daily) and Jakafi XR (extended release, once daily) now carry the same four indications:

    IndicationPopulation
    Intermediate- or high-risk myelofibrosis (primary MF, post-PV MF, post-ET MF)Adults
    Polycythemia vera with inadequate response to or intolerance of hydroxyureaAdults
    Steroid-refractory acute GVHDAdults and pediatric patients aged 12 and older
    Chronic GVHD after failure of 1 or 2 lines of systemic therapyAdults and pediatric patients aged 12 and older

    Jakafi XR is not approved for use in children with MF or PV; the MF and PV indications are adults only, identical to the original formulation. The GVHD indications cover pediatric patients aged 12 and older with the same weight and age constraints as the original formulation.

    Safety: What Applies to Jakafi XR

    Because Jakafi XR delivers the same drug at the same systemic exposure, its safety profile is established from the extensive clinical trial database of the original Jakafi across all approved indications. There are no new safety signals from Jakafi XR; the known adverse event profile of ruxolitinib applies in full.

    Most important safety considerations for prescribers and patients:

    Cytopenias: Thrombocytopenia, anemia, and neutropenia are the most common adverse reactions and can be severe. Dose adjustment or temporary interruption may be required based on complete blood count results. Monitoring is required before initiating and regularly during treatment.

    Serious infections: Ruxolitinib increases the risk of serious bacterial, mycobacterial, fungal, and viral infections. Tuberculosis reactivation has been reported. Patients should be evaluated for TB before starting treatment. Progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by JC virus, has been reported rarely with ruxolitinib. Monitoring for signs and symptoms of new neurological symptoms is important.

    Herpes zoster: Reactivation of varicella zoster virus (shingles) occurs at higher rates with ruxolitinib than with many other agents. Varicella zoster vaccination before initiating treatment is recommended where possible.

    Second primary malignancies: Non-melanoma skin cancers and lymphomas have been reported. Periodic skin examinations are recommended.

    Lipid elevations: Increases in cholesterol, LDL, and triglycerides have been reported. Assess lipid levels approximately 8 to 12 weeks after initiating treatment.

    Symptom exacerbation on discontinuation: Abrupt discontinuation or dose reduction of ruxolitinib in MF patients can cause rapid return of splenomegaly, constitutional symptoms, and in rare cases a syndrome resembling hemophagocytic lymphohistiocytosis (HLH). Dose tapering is recommended when discontinuation is necessary.

    Boxed warning: The FDA requires a boxed warning for thrombosis including fatal cases and for serious infections. These risks apply identically to Jakafi XR as to the original Jakafi.

    Dosing: The Key Dose Correspondence Table

    Jakafi XR doses correspond to Jakafi (immediate-release) doses at a 2.2:1 ratio reflecting the once-daily to twice-daily conversion. The standard approved correspondence is:

    Jakafi XR (once daily)Equivalent Jakafi IR doseClinical context
    55 mg once daily25 mg twice dailyStandard MF/PV dose; bioequivalence study dose
    Other XR dosesCorresponding IR twice-daily dosesPer prescribing information; dose adjustments mirror IR guidance

    Administration: Take Jakafi XR orally once daily at approximately the same time each day, with or without food. Swallow tablets whole; do not crush, chew, or split. If a dose is missed, take it as soon as possible on the same day; if the next day has arrived, skip the missed dose.

    Switching from Jakafi IR to Jakafi XR: Patients who are stable on Jakafi IR can switch to the corresponding Jakafi XR dose. No dose change is required; the XR dose that matches their current total daily IR exposure should be used. Because switching does not change drug exposure, no transition period or observation period beyond clinical routine is needed.

    Practical Implications: Who Benefits Most From the Switch

    Not every patient currently on Jakafi needs to switch to Jakafi XR. The clinical effect will be the same. The question is whether once-daily dosing offers enough practical benefit for a given patient to justify the conversation with their hematologist and the pharmacy change.

    Most likely to benefit from switching:

    • Patients who find twice-daily adherence difficult due to variable daily schedules, work constraints, or fatigue affecting evening dose reliability
    • Patients who are managing multiple twice-daily medications and for whom consolidating to once-daily simplifies overall regimen complexity
    • Newly initiating patients for whom once-daily is operationally simpler than twice-daily from the outset
    • Patients who have expressed frustration with the twice-daily scheduling burden to their hematologist

    Unlikely to need switching:

    • Patients who are well-established on Jakafi IR with no adherence concerns
    • Patients for whom the twice-daily timing provides useful structure or reminders anchored to established daily routines

    The key message for patients and clinicians is that Jakafi XR is not a better drug than Jakafi. It is the same drug with a more convenient schedule. In a chronic condition where medication duration is measured in years, a more convenient schedule is a genuine quality-of-life improvement for patients who want it.

    For related HED coverage of other formulation advances improving treatment convenience in chronic conditions, see our post on Awiqli, the first once-weekly basal insulin, which similarly reduced the injection frequency from 365 times per year to 52 for appropriate patients with type 2 diabetes.

    Sources

    FDA approval announcement: FDA approves ruxolitinib extended-release tablets (Jakafi XR). FDA.gov. May 1, 2026.

    Incyte press release: Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets. businesswire.com. May 1, 2026.

    Drugs.com approval news: Incyte Announces FDA Approval of Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD. drugs.com. May 2026.

    OncLive clinical coverage: FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis, Polycythemia Vera, and GVHD. onclive.com. May 2026.

    Targeted Oncology coverage: FDA Approves Extended-Release Ruxolitinib Once-Daily for MPNs and GVHD. targetedonc.com. May 2026.

    Cancer Therapy Advisor clinical review: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. cancertherapyadvisor.com. May 2026.

    CancerNetwork: FDA Approves Ruxolitinib Tablets for Hematologic Malignancies. cancernetwork.com. May 2026.

    CURE magazine coverage: FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions. curetoday.com. May 2026.

    Hematology Advisor: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. hematologyadvisor.com. May 2026.

    ASH 2025 bioequivalence poster: Gong X, Xun Z, Getsy J, McGee R, Mondick J, Punwani N. Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults. Blood. 2025;146(suppl 1):5045. doi:10.1182/blood-2025-5045

    Bioequivalence study registration: NCT06555081. ClinicalTrials.gov.

    Jakafi original FDA approval (2011): FDA approves ruxolitinib for myelofibrosis. FDA.gov. November 2011.

    Jakafi prescribing information: Jakafi XR (ruxolitinib) Prescribing Information. Incyte Corporation. 2026.

    FDA bioequivalence guidance: Bioequivalence Studies with Pharmacokinetic Endpoints. FDA.gov.

    Ruxolitinib mechanism overview: Ruxolitinib. StatPearls. NCBI.

    JAK-STAT pathway in MPNs: JAK-STAT Pathway in Myeloproliferative Neoplasms. PMC4207474.

    MF cancer overview: Myelofibrosis. American Cancer Society.

    PV overview: Polycythemia Vera. NHLBI.

    GVHD overview: GVHD Fact Sheet. NCI.

    Patient resources: MPN Research Foundation | Leukemia and Lymphoma Society: Myelofibrosis | National MPN Advocacy and Education | Bone Marrow Transplant Info Network

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about switching from Jakafi to Jakafi XR, or initiating ruxolitinib therapy in any approved indication, should be made in consultation with a qualified hematologist familiar with the patient’s full clinical history, current blood counts, and concurrent medications. Do not discontinue or change ruxolitinib doses without medical guidance.
  • BPDCN Has Been Diagnosed in Hundreds of Americans Each Year With Almost No Approved Treatment Options. Decnupaz Just Changed That.

    BPDCN Has Been Diagnosed in Hundreds of Americans Each Year With Almost No Approved Treatment Options. Decnupaz Just Changed That.

    📌 The essentials On May 27, 2026, the FDA approved Decnupaz (pivekimab sunirine-pvzy, AbbVie) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive hematologic malignancy. This is the second FDA-approved therapy for BPDCN and the first CD123-directed antibody-drug conjugate to receive FDA approval. Decnupaz is a first-in-class agent approved for both treatment-naive and relapsed or refractory BPDCN, making it applicable across all lines of therapy. Regulatory designations: Breakthrough Therapy Designation, Orphan Drug Designation, Priority Review. The clinical basis: Phase 1/2 CADENZA trial (NCT03386513), 84 adult patients (33 treatment-naive, 51 relapsed or refractory), open-label, single-arm. Primary endpoint: complete remission or clinical complete remission (CR/CRc) rate. Treatment-naive: 69.7% CR/CRc rate (95% CI 51.3 to 84.4%) at 21.5 months median follow-up; median duration of CR/CRc 9.7 months. Relapsed or refractory: 15.7% CR/CRc rate (95% CI 7.0 to 28.6%) at 24.1 months median follow-up; median duration of CR/CRc 9.2 months. Bridging to transplant: 39.4% of treatment-naive patients proceeded to post-study stem cell transplantation, a critical finding in a disease where bridging to transplant is a primary treatment goal. Boxed warning: hepatotoxicity including hepatic veno-occlusive disease (VOD). Dosing: 0.045 mg/kg intravenously over 15 to 30 minutes once every 3 weeks (21-day cycle).

    There are diseases that most physicians will never see in a career, not because they are mild or easily ignored, but because they are so rare that the entire diagnosed population in the United States numbers in the hundreds per year. Blastic plasmacytoid dendritic cell neoplasm is one of them.

    BPDCN is an aggressive blood cancer that arises from plasmacytoid dendritic cell precursors, presenting most often in older adults as skin lesions combined with bone marrow involvement and sometimes rapid spread to other organs. It carries a historically poor prognosis: median overall survival in historical series without transplantation has ranged from 8 to 14 months. The only previously approved targeted therapy for BPDCN was tagraxofusp (Elzonris), a CD123-directed cytotoxin approved in 2018, leaving a significant gap particularly in the relapsed and refractory setting.

    On May 27, 2026, the FDA approved Decnupaz (pivekimab sunirine-pvzy), a first-in-class CD123-directed antibody-drug conjugate developed by AbbVie (originally by ImmunoGen before AbbVie’s 2024 acquisition), for adult patients with BPDCN in both treatment-naive and relapsed or refractory settings. The approval is based on the CADENZA trial, which enrolled 84 patients across a disease population so rare that the trial itself represents one of the largest BPDCN clinical datasets ever assembled.

    What BPDCN Is and Why It Is So Difficult to Treat

    The cell of origin

    BPDCN arises from the malignant transformation of plasmacytoid dendritic cell precursors, a rare subset of immune cells that normally circulate in blood and reside in lymphoid tissues. Plasmacytoid dendritic cells (pDCs) are specialized innate immune cells responsible primarily for producing large quantities of type I interferons in response to viral infection. In BPDCN, these precursors undergo malignant transformation and proliferate in a manner that is neither classically leukemic nor typically lymphomatous but shares features of both.

    The disease was historically confusing to classify, previously known as agranular CD4+ CD56+ hematodermic neoplasm or blastic NK-cell lymphoma before its origin from pDC precursors was established. Its current classification as a distinct entity in the World Health Organization classification of hematologic malignancies reflects this now-understood biology.

    Clinical presentation and typical course

    BPDCN presents most commonly in adults over 60, with a strong male predominance (approximately 3:1 male-to-female ratio). The hallmark presentation is cutaneous involvement: bruise-like or reddish-brown skin lesions, nodules, or widespread plaques that can be widespread on the body surface. Bone marrow involvement is present in most patients at diagnosis, and peripheral blood involvement (leukemic phase) develops in many. The liver, spleen, and lymph nodes are other common sites.

    An important clinical complexity is that BPDCN frequently presents concurrently with or evolves from other hematologic malignancies, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and other myeloid neoplasms. In the CADENZA trial, 11 of the 33 treatment-naive patients had prior or concurrent cancer diagnoses in addition to BPDCN, reflecting real-world disease complexity.

    Disease progression is typically rapid. Without effective treatment, the course from initial presentation to systemic organ involvement can be weeks to months.

    The CD123 target: why BPDCN is uniquely susceptible CD123, the interleukin-3 receptor alpha chain (IL-3Rα), is a cell surface protein that is highly and consistently overexpressed on BPDCN cells across virtually all patients with the disease. IL-3 signaling through CD123 promotes the survival and proliferation of pDC precursors, and in BPDCN, this overexpression is not incidental but functionally important to the malignant cell’s biology. The near-universal CD123 overexpression in BPDCN makes it one of the best-matched malignancies for CD123-targeted therapy of any cancer type. Both approved BPDCN therapies, tagraxofusp and now Decnupaz, exploit this target. The CADENZA trial required CD123 positivity confirmed by flow cytometry or immunohistochemistry for enrollment, ensuring that all patients in the trial had the target expression pattern needed for the drug to work.

    How Decnupaz Works: A First-in-Class ADC Mechanism

    Decnupaz (pivekimab sunirine-pvzy) is an antibody-drug conjugate (ADC) with three distinct components:

    The antibody: A high-affinity anti-CD123 monoclonal antibody that binds specifically to CD123 expressed on BPDCN cells. When the antibody binds CD123, the drug-receptor complex is internalized into the cell.

    The linker: A cleavable linker that connects the antibody to the payload. After internalization, the linker is cleaved by intracellular enzymes, releasing the active payload inside the cancer cell.

    The payload: An indolinobenzodiazepine pseudodimer (IGN), a potent DNA alkylating agent that alkylates DNA and causes single-strand DNA breaks without crosslinking. The mechanism of single-strand DNA damage without crosslinking is pharmacologically distinct from conventional alkylating chemotherapy, which typically crosslinks DNA. This distinction is designed to produce cytotoxicity in the targeted cancer cells while limiting some of the toxicity patterns associated with conventional alkylators.

    This mechanism is what makes pivekimab sunirine a first-in-class agent: no previously approved drug uses an indolinobenzodiazepine pseudodimer payload in an ADC. The combination of the CD123-targeting antibody with this specific payload represents a novel mechanistic approach to BPDCN treatment.

    Decnupaz differs from tagraxofusp in mechanism: tagraxofusp is a CD123-directed cytotoxin that consists of IL-3 fused to truncated diphtheria toxin, producing cell killing through a protein synthesis inhibition mechanism. Decnupaz delivers a DNA-damaging payload via ADC technology, offering a different mechanism of action for patients who have failed or cannot receive tagraxofusp.

    The CADENZA Trial: Full Results

    Design

    CADENZA (NCT03386513) is a multicenter, open-label, single-arm Phase 1/2 trial that enrolled adults aged 18 and older with BPDCN with CD123 positivity confirmed by flow cytometry or immunohistochemistry and no evidence of active central nervous system disease. Two distinct cohorts were enrolled:

    • Treatment-naive BPDCN (n=33): patients with no prior BPDCN-directed systemic therapy
    • Relapsed or refractory BPDCN (n=51): patients who had received at least one prior line of therapy

    The primary efficacy endpoint was the rate of complete remission (CR) or clinical complete remission (CRc). CR was defined as complete resolution of all BPDCN manifestations with full hematologic recovery. CRc was defined as complete resolution of all BPDCN manifestations with incomplete hematologic recovery (analogous to the CRi designation used in AML).

    Primary endpoint results: treatment-naive cohort

    OutcomeTreatment-naive BPDCN (n=33)
    CR/CRc rate69.7% (95% CI 51.3 to 84.4%)
    Number of patients achieving CR/CRc23 of 33
    Median follow-up21.5 months
    Median duration of CR/CRc9.7 months (95% CI 2.9 to not estimable)
    Patients proceeding to post-study stem cell transplantation39.4% (13 of 33)
    Median overall survival (all treatment-naive, n=33)16.6 months (95% CI 11.4 to not reached)
    12-month OS rate64% (95% CI 44.9 to 77.5%)
    18-month OS rate44% (95% CI 26.7 to 60.3%)

    Primary endpoint results: relapsed or refractory cohort

    OutcomeRelapsed or refractory BPDCN (n=51)
    CR/CRc rate15.7% (95% CI 7.0 to 28.6%)
    Number of patients achieving CR/CRc8 of 51
    Median follow-up24.1 months
    Median duration of CR/CRc9.2 months (range 2.7 to 27.6 plus months)

    Source: CADENZA trial, NCT03386513. FDA approval notice, May 27, 2026. OncLive and Targeted Oncology clinical coverage.

    The transplant bridge finding: the most clinically important secondary result

    In the treatment-naive cohort, 39.4% of patients (13 of 33) proceeded to post-study stem cell transplantation after achieving response with Decnupaz. This finding is critically important in BPDCN because allogeneic stem cell transplantation is the only treatment approach associated with potential long-term cure in this disease. The primary role of induction therapy in BPDCN is often conceptualized as achieving a remission deep enough to bridge the patient to transplant while they remain in adequate condition to tolerate it.

    A CR/CRc rate of 69.7% in treatment-naive patients, with 39.4% successfully bridging to transplant, represents a meaningful clinical achievement for a disease where achieving remission adequate for transplant eligibility has historically been extremely difficult.

    The durability finding in the relapsed or refractory cohort also deserves specific attention: the median CR/CRc duration of 9.2 months in heavily pretreated patients, in a setting where overall response rates are low (15.7%), means that the patients who do respond achieve durable remissions comparable in length to those seen in the treatment-naive setting. This suggests that the drug’s mechanism produces meaningful responses when it works, across disease stages.

    Why single-arm trial data is accepted for ultra-rare cancer approvals BPDCN affects an estimated 500 to 1,000 patients per year in the United States. Running a randomized controlled trial with a placebo or active comparator arm in a disease this rare would take many years of enrollment, during which patients in the control arm would face disease progression without the study drug. The FDA routinely accepts single-arm evidence for ultra-rare malignancies when: the disease has an established and poor natural history; the effect size (here, 69.7% CR/CRc versus historical rates well below this) is large enough to be interpretable without a concurrent control; and adequate regulatory designations (Breakthrough, Orphan) are in place. The CADENZA approval follows this same logic used for tagraxofusp in 2018 and for multiple other ultra-rare cancer approvals. The absence of a randomized comparator reflects the rarity of the disease, not a weakness in the evidence standard applied.

    Safety: What the Prescribing Information Covers

    Boxed warning: hepatotoxicity including hepatic veno-occlusive disease

    Decnupaz carries a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome. VOD is a serious condition in which small hepatic veins are obstructed, causing liver damage that can range from mild and self-limiting to severe and fatal. It is a recognized complication of certain chemotherapy regimens and stem cell transplantation conditioning and can be life-threatening when severe.

    The boxed warning means:

    • Liver function tests must be monitored before each dose and as clinically indicated throughout treatment
    • Dose modifications or discontinuation are required for significant hepatotoxicity
    • Patients proceeding to stem cell transplantation after Decnupaz require careful management of VOD risk in the transplant setting

    Warnings and precautions

    Infusion-related reactions (IRRs): Infusion-related reactions occurred in clinical trials. Patients should be premedicated per the prescribing information before each infusion and monitored throughout administration. For severe reactions, the infusion should be stopped and not restarted.

    Edema: Fluid retention and edema are documented with CD123-targeted therapies in BPDCN. Monitor for new or worsening edema, particularly in patients with baseline cardiac or renal disease.

    Sulfite allergic reactions: Decnupaz contains sodium metabisulfite, which can cause allergic-type reactions including anaphylaxis and bronchospasm in susceptible individuals. The risk is higher in patients with asthma. Patients should be asked about sulfite sensitivity before initiating therapy.

    Embryo-fetal toxicity: Based on the mechanism of action (DNA alkylation), Decnupaz can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the final dose.

    Dosing and Administration

    ParameterDetails
    Dose0.045 mg/kg intravenously once every 3 weeks (21-day cycle)
    Infusion durationApproximately 15 to 30 minutes
    Dose calculationBased on actual body weight
    CyclesContinue until disease progression or unacceptable toxicity
    FormulationLyophilized cake for injection; requires reconstitution prior to administration
    PremedicationPer prescribing information; required before each infusion

    What This Approval Means in Context

    Decnupaz vs. tagraxofusp

    Decnupaz is the second approved therapy for BPDCN. Tagraxofusp (Elzonris), approved in 2018, remains the reference treatment for newly diagnosed BPDCN and demonstrated an overall response rate of 90% in treatment-naive patients in its pivotal trial. However, tagraxofusp carries a boxed warning for capillary leak syndrome, a serious and potentially life-threatening vascular complication that limits its use in some patients.

    Decnupaz offers a mechanistically distinct option across both treatment-naive and relapsed settings, with a different toxicity profile. No head-to-head comparison between tagraxofusp and Decnupaz exists; the choice between them in the treatment-naive setting will depend on institutional experience, patient-specific factors including comorbidities that affect tolerance of each product’s boxed warning risks, and the treating hematologist’s clinical judgment.

    The approval of Decnupaz for relapsed or refractory disease is particularly significant because tagraxofusp’s pivotal data was primarily in the treatment-naive setting, and until now there has been no approved targeted therapy specifically for patients who have progressed after first-line treatment.

    The AbbVie acquisition context

    Pivekimab sunirine was originally developed by ImmunoGen, Inc., a company that pioneered ADC technology and developed multiple ADCs including mirvetuximab soravtansine (Elahere) for ovarian cancer. In early 2024, AbbVie acquired ImmunoGen for approximately $10.1 billion, a transaction that included pivekimab sunirine in the pipeline. The BLA for Decnupaz was submitted to the FDA in September 2025 and approved May 27, 2026.

    For Patients and Clinicians

    For patients diagnosed with BPDCN

    BPDCN is rare enough that most patients will be referred to specialized hematology centers with experience in this disease shortly after diagnosis. Treatment decisions for BPDCN, including the choice between Decnupaz and tagraxofusp in treatment-naive disease, and whether to pursue stem cell transplantation, belong with a board-certified hematologic oncologist familiar with this specific diagnosis.

    Decnupaz is now an FDA-authorized option for adults with BPDCN in any line of therapy. For patients who have relapsed after prior treatment, including tagraxofusp, this is the first approved targeted therapy available in that setting.

    The Leukemia and Lymphoma Society (LLS) and NORD maintain current clinical information on BPDCN including specialist referral resources. For clinical trial opportunities, ClinicalTrials.gov lists currently enrolling studies for BPDCN. AbbVie’s patient support program provides access resources for Decnupaz at abbvie.com/BPDCN.

    For related HED coverage of other ADC approvals and hematologic malignancy treatment advances in 2026, see our post on Inqovi plus venetoclax, the first all-oral AML regimen for treatment-ineligible patients, and our post on the Immgolis biosimilar approval and the TNF inhibitor market for autoimmune conditions.

    Sources

    FDA approval announcement: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy. FDA.gov. May 27, 2026.

    AbbVie press release: AbbVie Announces FDA Approval of Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. abbvie.com. May 27, 2026.

    Drugs.com approval news: FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. drugs.com. May 27, 2026.

    ASCO Post clinical summary: BPDCN: FDA Approves Pivekimab Sunirine-pvzy. ascopost.com. May 2026.

    CancerNetwork detailed coverage: FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy. cancernetwork.com. May 2026.

    Targeted Oncology full trial summary: FDA Approves Pivekimab Sunirine for BPDCN. targetedonc.com. May 2026.

    OncLive OS data coverage: FDA Approves Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm. onclive.com. May 2026.

    ONS clinical summary: FDA Approves Pivekimab Sunirine-Pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm. ons.org. May 2026.

    CURE magazine coverage: FDA OKs Decnupaz for Adults With Blastic Plasmacytoid Dendritic Cell Neoplasm. curetoday.com. May 2026.

    Medscape coverage: FDA Approves Novel Targeted Therapy for Rare Blood Cancer. medscape.com. May 2026.

    CADENZA trial registration: NCT03386513. ClinicalTrials.gov.

    Tagraxofusp FDA approval (reference): FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. FDA.gov. 2018.

    BPDCN disease overview: Blastic Plasmacytoid Dendritic Cell Neoplasm. StatPearls. NCBI.

    BPDCN GARD overview: Blastic Plasmacytoid Dendritic Cell Neoplasm. rarediseases.info.nih.gov.

    Hepatic VOD reference: Hepatic Veno-Occlusive Disease. PMC6016375.

    ADC overview: Antibody-Drug Conjugate. cancer.gov.

    Breakthrough Therapy Designation: Breakthrough Therapy. FDA.gov.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    AbbVie acquisition of ImmunoGen: AbbVie Completes Acquisition of ImmunoGen. abbvie.com.

    Patient resources: Leukemia and Lymphoma Society: BPDCN | NORD: BPDCN | NIH GARD: BPDCN | ClinicalTrials.gov: BPDCN

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. BPDCN is an ultra-rare malignancy requiring specialist care. Treatment decisions should be made in close consultation with a board-certified hematologic oncologist with experience in rare blood cancers.